Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Thioaptamer interactions with prion proteins: sequence-specific and non-specific binding sites.

David J King1, Jiri G Safar, Giuseppe Legname

  • 1Institute for Neurodegenerative Diseases, University of California San Francisco, CA 94143-0518, USA.

Journal of Molecular Biology
|May 8, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prion-like transmission and propagation of human β-amyloid to the bank vole rodent model.

Acta neuropathologica·2026
Same author

[211At]Astatine-Based Conditioning with a Humanized CD45 Antibody for Autologous Hematopoietic Stem Cell Gene Therapy.

Blood·2026
Same author

Flipping plankton.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same author

IL-11 receptor is a novel target for drug development with pharmacological activity in fibro-inflammatory disease.

Scientific reports·2026
Same author

Multi-target approaches to prion disease drug discovery: a status update.

Expert opinion on drug discovery·2026
Same author

Therapeutic effect of IL-11 inhibition on the pathogenesis of thyroid eye disease.

Journal of molecular endocrinology·2025

Researchers developed a specific DNA thioaptamer that binds to prion protein (PrP) with high affinity. This binding is dependent on the thioaptamer

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Prion Disease Research

Background:

  • Distinguishing specific nucleic acid interactions from non-specific binding to prion protein (PrP) is crucial.
  • Developing selective ligands for PrP is essential for understanding its function and pathology.
  • PrP's interaction with nucleic acids remains an area requiring detailed investigation.

Purpose of the Study:

  • To develop selective DNA thioaptamers that bind to prion protein (PrP).
  • To identify the specific binding sites and sequence requirements for thioaptamer-PrP interaction.
  • To characterize the affinity and specificity of thioaptamer binding to PrP from different species.

Main Methods:

  • Selection of single-stranded DNA thioaptamer libraries against recombinant Syrian hamster PrP (recSHaPrP).

Related Experiment Videos

  • Characterization of binding affinity using thioaptamer 97 and PrP from Syrian hamster, bovine, and human sources.
  • Analysis of critical sequence and backbone modifications within the thioaptamer for high-affinity binding.

    • Main Results:

    • A 12-base consensus sequence within a 40-base thioaptamer (designated 97) demonstrated high-affinity binding to recSHaPrP (0.58 nM).
    • Binding affinity varied across different PrP species (Syrian hamster, bovine, human), indicating sequence dependence.
    • High-affinity binding was mediated by the specific sequence GACACAAGCCGA and critical backbone modifications.

    Conclusions:

    • DNA thioaptamers can be developed as highly specific ligands for prion protein (PrP).
    • Thioaptamer 97 binding to PrP is dependent on PrP primary structure, thioaptamer sequence, and backbone modifications.
    • These findings provide a foundation for developing diagnostic or therapeutic tools targeting PrP.